Qualified Persons
“At Chartered Pharma Consultants, we collaborate with clients to develop and execute streamlined functional strategies that ensure long-lasting compliance by seamlessly integrating technical, scientific, and regulatory knowledge.”
“At Chartered Pharma Consultants, we collaborate with clients to develop and execute streamlined functional strategies that ensure long-lasting compliance by seamlessly integrating technical, scientific, and regulatory knowledge.”
Daily news
Everything about the business world in one place.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in
Ljilja Peltola Consultant
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tem por incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
Cedric Xiong Ceo
Best deals
Special offer worth investing in, choose your pack today!
Dr Durgaprasad Seeram
Director / Senior Consultant
Daniel Dooley
Director of GxP services / Senior Consultant
Dr John Folan
Qualified Person (EU) / Senior Consultant
Puneet Kumar
Qualified person (U.K.) / Senior Consultant
Richard Baitson
Lead Auditor / Senior Consultant
QA & Regulatory Specialists
CSDDD Omnibus Explained – Practical interpretation (Pharma) Scenerio -2
Where the API supplier sits under CSDDD Key point: The API manufacturer in India/China is a: Direct business partner (Tier 1) Even though geographically outside the EU. Why this is
CSDDD Omnibus Explained – Practical interpretation (Pharma) Scenerio -1
Case: EU MAH → CMO (India) → API supplier (India) Under Omnibus CSDDD: Tier Entity Legal CSDDD Expectation Practical Pharma Reality Tier 0 EU MAH ✔ Fully in scope under the C
CSDDD Omnibus Explained
The Directive requires companies to identify, prevent, mitigate, and remediate: Environmental (E) impacts Social / Human Rights (S) impacts These are grounded in international stan
What truly defines a “Successful” Manager?
 In the evolving landscape of leadership, we often debate what makes a manager truly effective. Is it deep technical expertise? Is it soft skills? Or is it something else entirely
FDA Warning Letter to Abbott Diabetes Care — Key Quality System Failures
Recently the U.S. Food and Drug Administration issued a Warning Letter to Abbott Diabetes Care following a routine inspection of their Alameda, CA facility that raised serious Qual
FDA Form 483 Deep Dive: Sterile Manufacturing Under the Microscope.
The U.S. Food and Drug Administration (FDA) issued a Form 483 to Eugia Pharma Specialities Limited, Sangareddy, Telangana, 502307 India following a January–February 2026 inspect
The True Cost of Non-Compliant Promotion of Medicinal Products…
Recent years have provided stark reminders of the financial, regulatory, and societal consequences of failures in pharmaceutical compliance and governance. 🔶 One widely cited ex
A comprehensive summary of the FDA Form 483 issued to Aurobindo Pharma Limited,
Unit VII (Inspection dated Jan 28 – Feb 10 2026), including what went wrong at the quality system level — root causes, system failures, and broader quality-management insights
Why “Precision” Isn’t Enough for the FDA: A Lesson in Method Equivalency.
 I’ve been diving deep into a specific FDA 483 observation recently that every Analytical Lead and QA Manager should keep on their radar. It highlights a common trap: confusing
